General News | BioCryst Pharmaceuticals, Inc.

Skip to main navigation

Home
News & Events
Press Releases Events & Presentations Media Materials
Stock
Stock Quote & Chart Historic Stock Lookup Analyst Coverage
Corporate Governance
Board of Directors Committee Composition Code of Conduct and Ethics Committee Charters Corporate Responsibility
Finance & Filings
Financial Profile SEC Documents Proxy Online Quarterly Results
Investor Resources
Investor FAQ Email Alerts RSS News Feeds

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

Read more about BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

Read more about BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

Read more about BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

Read more about BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst to Present at Upcoming Investor Conferences

Read more about BioCryst to Present at Upcoming Investor Conferences

BioCryst to Report First Quarter 2026 Financial Results on May 6

Read more about BioCryst to Report First Quarter 2026 Financial Results on May 6

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

Read more about BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

Page 1
Next page

Subscribe to General News

Contact Investor Relations

investorrelations@biocryst.com

Investor Tools

Print Page
Printed Materials
Email Alerts
RSS News Feeds
Share Page

© BioCryst Pharmaceuticals, Inc. All Rights Reserved. 2026

Facebook
Twitter
LinkedIn
RSS